Historical Stock Price
CASC historical stock prices picture
CASC (CASC) has the following price history information. Looking back at CASC historical stock prices for the last five trading days, on March 06, 2018, CASC opened at $9.98, traded as high as $10.00 and as low as $9.98, and closed at $10.00. Trading volume was a total of 419.00K shares. On March 07, 2018, CASC opened at $9.99, traded as high as $10.01 and as low as $9.99, and closed at $10.00. Trading volume was a total of 473.50K shares. On March 08, 2018, CASC opened at $10.00, traded as high as $10.03 and as low as $9.99, and closed at $10.02. Trading volume was a total of 438.30K shares. On March 09, 2018, CASC opened at $10.02, traded as high as $10.02 and as low as $10.02, and closed at $10.02. Trading volume was a total of 2.00K shares. On March 12, 2018, CASC opened at $10.02, traded as high as $10.02 and as low as $10.02, and closed at $10.02. Trading volume was a total of 0 shares.

CASC Historical Stock Prices By Date:

CASC historical cagr picture

Below, we examine the compound annual growth rate — CAGR for short — of an investment into CASC shares, starting with a $10,000 purchase of CASC, and working forward through the historical stock price information to today.

Growth of $10,000.00
Without Dividends Reinvested

Start date: 04/01/2014
End date: 03/12/2018
Start price/share: $18.96
End price/share: $10.02
Dividends collected/share: $0.00
Total return: -47.15%
Average Annual Total Return: -14.92%
Starting investment: $10,000.00
Ending investment: $5,284.00
Years: 3.95
Date Open High Low Close Volume
03/06/2018 $9.98 $10.00 $9.98 $10.00 419.00K
03/07/2018 $9.99 $10.01 $9.99 $10.00 473.50K
03/08/2018 $10.00 $10.03 $9.99 $10.02 438.30K
03/09/2018 $10.02 $10.02 $10.02 $10.02 2.00K
03/12/2018 $10.02 $10.02 $10.02 $10.02 0
Cascadian Therapeutics is a clinical-stage biopharmaceutical company focused on the development of therapeutic products for the treatment of cancer. Co.'s primary development candidate, tucatinib, is an orally bioavailable, potent tyrosine kinase inhibitor that is selective for HER2, a growth factor receptor that is over-expressed in about 20.0% of breast cancers. Co. is developing tucatinib for the treatment of HER2-positive metastatic breast cancer. Co.'s earlier stage product candidate, CASC-578, is a checkpoint kinase 1 cell cycle inhibitor that is an orally available, small molecule kinase inhibitor and additionally Co. has an antibody against an immuno-oncology target known as TIGIT.
Date Close
03/06/2018$10.00
03/07/2018$10.00
03/08/2018$10.02
03/09/2018$10.02
03/12/2018$10.02
CASC is categorized under the Healthcare sector; below are some other companies in the same sector:

CASI Historical Stock Prices
CASM Historical Stock Prices
CATB Historical Stock Prices
CATS Historical Stock Prices
CBAY Historical Stock Prices
CBIO Historical Stock Prices
CBLI Historical Stock Prices
CBM Historical Stock Prices
CBMG Historical Stock Prices
CBMX Historical Stock Prices

Email EnvelopeFree CASC Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts


CASC Historical Stock Prices | www.HistoricalStockPrice.com | Copyright © 2013 - 2024, All Rights Reserved

Nothing in www.HistoricalStockPrice.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. Split history database is not guaranteed to be complete or free of errors. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Service. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.
X
Wait! Don't leave yet.
Want to receive our latest research absolutely free?


Click the button below for your complimentary copy of Your Early Retirement Portfolio: Dividends Up to 9.5%—Every Month—Forever.

You'll discover the details on 4 stocks and funds that pay you massive dividends as high as 9.5%.